Abstract
The outbreak of COVID-19, caused by the novel coronavirus SARS-CoV-2, has been linked to a notable rise in mucormycosis cases, particularly evident during the second wave in the summer of 2021. Mucormycosis, characterized by its aggressive nature and high mortality rates, requires rapid identification and intervention. Factors such as poorly controlled blood sugar levels, corticosteroid usage, and COVID-19-related immune compromise are significant contributors to its development. The objective of this review is to analyze the incidence, progression, clinical manifestations, and treatment approaches of mucormycosis, drawing from a selection of 16 pertinent articles published between 2009 and 2022, and accessed through databases like PubMed and Google Scholar.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
